<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" media="screen" href="/~d/styles/rss2full.xsl"?><?xml-stylesheet type="text/css" media="screen" href="http://feeds.feedburner.com/~d/styles/itemcontent.css"?><rss xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0">
  <channel>
    <title><![CDATA[Optimal Use Topics]]></title>
    <link>http://www.cadth.ca/xml.php/en/products/optimal-use</link>
    <description />
    <pubDate>Thu, 23 May 2013 14:18:36 -0400</pubDate>
    <generator>Zend_Feed</generator>
    <docs>http://blogs.law.harvard.edu/tech/rss</docs>
    <atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="self" type="application/rss+xml" href="http://feeds.feedburner.com/cadth/en/OptimalUseTopics" /><feedburner:info xmlns:feedburner="http://rssnamespace.org/feedburner/ext/1.0" uri="cadth/en/optimalusetopics" /><atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="hub" href="http://pubsubhubbub.appspot.com/" /><item>
      <title><![CDATA[Point-of-Care Testing of the International Normalized Ratio (INR) for Patients Taking Warfarin or Other Vitamin K Antagonists]]></title>
      <link>http://www.cadth.ca/en/products/optimal-use/poc-inr</link>
      <description />
      <content:encoded />
      <pubDate>Thu, 18 Apr 2013 11:35:45 -0400</pubDate>
    </item>
    <item>
      <title><![CDATA[High-Sensitivity Cardiac Troponin for the Rapid Diagnosis of Acute Coronary Syndrome in the Emergency Department]]></title>
      <link>http://www.cadth.ca/en/products/optimal-use/high-sensitivity-troponin</link>
      <description />
      <content:encoded />
      <pubDate>Tue, 29 Jan 2013 15:15:52 -0500</pubDate>
    </item>
    <item>
      <title><![CDATA[Large Volumetric Infusion Pumps: Inventory Management and Usability Surveys]]></title>
      <link>http://www.cadth.ca/en/products/optimal-use/volumetric-infusion-pumps</link>
      <description><![CDATA[<p>Large Volumetric Infusion Pumps:&nbsp;Inventory Management and Usability Surveys</p>]]></description>
      <content:encoded><![CDATA[<p>Large Volumetric Infusion Pumps:&nbsp;Inventory Management and Usability Surveys</p>]]></content:encoded>
      <pubDate>Thu, 26 Apr 2012 15:57:19 -0400</pubDate>
    </item>
    <item>
      <title><![CDATA[Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses]]></title>
      <link>http://www.cadth.ca/en/products/optimal-use/atypical-antipsychotics-for-schizophrenia</link>
      <description><![CDATA[<p>Optimal use of atypical antipsychotic combination therapy, as well as high-dosing treatment strategies in adolescents and adults with schizophrenia</p>]]></description>
      <content:encoded><![CDATA[<p>Optimal use of atypical antipsychotic combination therapy, as well as high-dosing treatment strategies in adolescents and adults with schizophrenia</p>]]></content:encoded>
      <pubDate>Thu, 15 Dec 2011 11:15:00 -0500</pubDate>
    </item>
    <item>
      <title><![CDATA[Warfarin Management for Thromboembolic Events in Atrial Fibrillation]]></title>
      <link>http://www.cadth.ca/en/products/optimal-use/warfarin-management</link>
      <description><![CDATA[<p>The Canadian Agency for Drugs and Technologies in Health (CADTH) is undertaking a project on the optimal management of warfarin to prevent stroke and other thromboembolic events in patients with atrial fibrillation. Warfarin</p>]]></description>
      <content:encoded><![CDATA[<p>The Canadian Agency for Drugs and Technologies in Health (CADTH) is undertaking a project on the optimal management of warfarin to prevent stroke and other thromboembolic events in patients with atrial fibrillation. Warfarin</p>]]></content:encoded>
      <pubDate>Mon, 15 Aug 2011 18:53:21 -0400</pubDate>
    </item>
    <item>
      <title><![CDATA[Medical Isotopes and Alternatives for Diagnostic Imaging]]></title>
      <link>http://www.cadth.ca/en/products/optimal-use/medical-isotopes-projct</link>
      <description><![CDATA[<p>The Canadian Agency for Drugs and Technologies in Health (CADTH) is undertaking a multifaceted project to support greater efficiency and effectiveness in the health system management of the medical isotope technetium-99m (99mTc)&hellip;.</p>]]></description>
      <content:encoded><![CDATA[<p>The Canadian Agency for Drugs and Technologies in Health (CADTH) is undertaking a multifaceted project to support greater efficiency and effectiveness in the health system management of the medical isotope technetium-99m (99mTc)&hellip;.</p>]]></content:encoded>
      <pubDate>Mon, 23 May 2011 14:01:20 -0400</pubDate>
    </item>
    <item>
      <title><![CDATA[Solvent/Detergent-Treated Human Plasma]]></title>
      <link>http://www.cadth.ca/en/products/optimal-use/solvent-detergent-treated-human-plasma</link>
      <description><![CDATA[<p>Clinical and cost-effectiveness review of solvent-detergent-treated human plasma and recommendations for optimal use in high-risk populations</p>]]></description>
      <content:encoded><![CDATA[<p>Clinical and cost-effectiveness review of solvent-detergent-treated human plasma and recommendations for optimal use in high-risk populations</p>]]></content:encoded>
      <pubDate>Tue, 12 Jul 2011 10:59:32 -0400</pubDate>
    </item>
    <item>
      <title><![CDATA[1.5 Tesla Magnetic Resonance Imaging Scanners Compared with 3.0 Tesla Magnetic Resonance Imaging Scanners]]></title>
      <link>http://www.cadth.ca/en/products/optimal-use/15-tesla-magnetic-resonance</link>
      <description><![CDATA[<p>Guidance for Canadian decision-makers based on a review of the comparative clinical benefits, limitations, and safety considerations of 1.5 Tesla MRI scanners and 3.0 Tesla MRI scanners</p>]]></description>
      <content:encoded><![CDATA[<p>Guidance for Canadian decision-makers based on a review of the comparative clinical benefits, limitations, and safety considerations of 1.5 Tesla MRI scanners and 3.0 Tesla MRI scanners</p>]]></content:encoded>
      <pubDate>Mon, 23 May 2011 14:05:02 -0400</pubDate>
    </item>
    <item>
      <title><![CDATA[Second- and Third-line Therapies for Type 2 Diabetes]]></title>
      <link>http://www.cadth.ca/en/products/optimal-use/second-line-therapies</link>
      <description><![CDATA[<p>Optimal prescribing and use of second- and third-line therapies for patients with type 2 diabetes</p>]]></description>
      <content:encoded><![CDATA[<p>Optimal prescribing and use of second- and third-line therapies for patients with type 2 diabetes</p>]]></content:encoded>
      <pubDate>Mon, 23 May 2011 14:05:34 -0400</pubDate>
    </item>
    <item>
      <title><![CDATA[Self-Monitoring of Blood Glucose]]></title>
      <link>http://www.cadth.ca/en/products/optimal-use/self-monitoring</link>
      <description><![CDATA[Optimal prescribing and use of blood glucose test strips for the treatment and management of diabetes]]></description>
      <content:encoded><![CDATA[Optimal prescribing and use of blood glucose test strips for the treatment and management of diabetes]]></content:encoded>
      <pubDate>Mon, 23 May 2011 14:05:52 -0400</pubDate>
    </item>
    <item>
      <title><![CDATA[Insulin Analogue Therapy for Diabetes Management]]></title>
      <link>http://www.cadth.ca/en/products/optimal-use/insulin-analog-therapy</link>
      <description><![CDATA[Optimal prescribing and use of rapid- and long-acting insulin analogues for the treatment and management of diabetes]]></description>
      <content:encoded><![CDATA[Optimal prescribing and use of rapid- and long-acting insulin analogues for the treatment and management of diabetes]]></content:encoded>
      <pubDate>Mon, 23 May 2011 14:06:18 -0400</pubDate>
    </item>
    <item>
      <title><![CDATA[Proton Pump Inhibitor Therapy]]></title>
      <link>http://www.cadth.ca/en/products/optimal-use/proton-pump-inhibitor-therapy</link>
      <description><![CDATA[<p>Optimal prescribing and use of proton pump inhibitors for the treatment of common gastrointestinal conditions</p>]]></description>
      <content:encoded><![CDATA[<p>Optimal prescribing and use of proton pump inhibitors for the treatment of common gastrointestinal conditions</p>]]></content:encoded>
      <pubDate>Mon, 23 May 2011 14:06:37 -0400</pubDate>
    </item>
    <item>
      <title><![CDATA[Hip Protectors]]></title>
      <link>http://www.cadth.ca/en/products/optimal-use/policy-guid-hip-protect</link>
      <description><![CDATA[<p>Hip fractures are a significant health risk for seniors. Hip fractures  in long-term care residents may be reduced by preventing and treating  osteoporosis, preventing falls, and by using hip protectors&hellip;</p>]]></description>
      <content:encoded><![CDATA[<p>Hip fractures are a significant health risk for seniors. Hip fractures  in long-term care residents may be reduced by preventing and treating  osteoporosis, preventing falls, and by using hip protectors&hellip;</p>]]></content:encoded>
      <pubDate>Tue, 12 Jul 2011 10:56:39 -0400</pubDate>
    </item>
  </channel>
</rss>
